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Xanthophylls have attracted a lot of interest since their health benefits were documented. Unfortunately, studying their intestinal absorption is often
affected by high baseline levels present in the fasting plasma. As a-cryptoxanthin is rarely found in the traditional European diet, its concentration
in human plasma is extremely low. A pilot human intervention study was designed using a-cryptoxanthin for the first time as a marker xanthophyll
in a minimally formulated cellulose-based supplement. a-Cryptoxanthin was administered in gelatin soft-gel capsules in multiple doses of 156mg/
d to three male volunteers (age 27·3 (SD 4·7) years; BMI 21·6 (SD 0·3) kg/m2) for 16 d after a 2-week carotenoid depletion period. Fasting blood
samples were taken before the intervention and after 3, 6, 9, 13 and 16 d. Plasma HPLC analyses allowed for determination of the concentration;
liquid chromatography–MS in the single ion monitoring mode was used to confirm peak assignment. The concentrations of a-cryptoxanthin
increased significantly after only 3 d of supplementation. The concentration-time plots showed a characteristic shape with a first maximum
after day 6, a decline until day 9 and a gradual second rise until the end of the study. Standardisation of plasma a-cryptoxanthin concentrations
to triacylglycerol or total cholesterol did not influence the characteristics. The maximum concentrations reached at the end of the intervention
period ranged from 0·077 to 0·160mmol/l. These results suggest a high intestinal absorption and an enrichment of a-cryptoxanthin in the
plasma even from a minimally formulated cellulose-based supplement.
a-Cryptoxanthin: Plasma xanthophyll response: Liquid chromatography–mass spectroscopy in the single ion monitoring mode:
Pilot studies
Xanthophylls have attracted a lot of interest since it was pre-
sumed that an increased nutritional uptake might provide pro-
tection against certain diseases. In particular, the health
benefits of lutein, zeaxanthin and b-cryptoxanthin have been
well documented in the last decade. For example, the non-pro-
vitamin A xanthophylls lutein and zeaxanthin may protect the
human eye from age-related macula degeneration and catar-
acts (Beatty et al. 1999; Mares-Perlman et al. 2002). In
accordance with their high nutritional value, plants rich in
lutein such as Tagetes erecta (Hadden et al. 1999; Breithaupt
et al. 2002) are actually cultivated on a large scale. b-Crypto-
xanthin was recently associated with an increased protein for-
mation and/or prevention of loss of proteins in man and
animals (Eichinger et al. 2005). A high plasma level of
b-cryptoxanthin has also been linked to a protective effect
against rheumatoid arthritis (Cerhan et al. 2003; Pattison
et al. 2005) and – together with Zn at low concentrations –
to a positive effect on bone components in vitro (Uchiyama
et al. 2005). Craft et al. (2004) found that b-cryptoxanthin
belongs to the major xanthophylls in the human brain,
where particularly the frontal cortex, which is generally sus-
ceptible to Alzheimer’s disease, exhibited higher concen-
trations than other parts. However, a possible mode of
action still remains to be elucidated.
Looking into more detail, b-cryptoxanthin is the most
popular representative of a group of three structural isomers
(Fig. 1). In accordance with the isoprenoid biosynthetic path-
way in plants (van den Berg et al. 2000), enzymic hydroxy-
lation of symmetric b-carotene leads to the formation of
b-cryptoxanthin, whereas the same reaction starting from
asymmetric a-carotene (b,1-carotene) gives rise to two
reaction products: b,1-carotene-30-ol (a-cryptoxanthin) and
b,1-carotene-3-ol (zeinoxanthin). This designation is in
accordance with modern xanthophyll nomenclature. However,
it must be highlighted that the structural cryptoxanthin isomers
a-cryptoxanthin and zeinoxanthin were often confused in
older literature, causing misinterpretation of the carotenoid
content of food (Schlatterer & Breithaupt, 2005).
Due to the presence of unsubstituted b-ionone rings, a- and
b-cryptoxanthin act as provitamin-A precursors. b-Crypto-
xanthin and zeinoxanthin are found in numerous food plants.
b-Cryptoxanthin is present in high amounts in red paprika,
citrus fruits, persimmon and in tropical fruits such as papaya
and mango (Chandrika et al. 2003; Mele´ndez-Martı´nez et al.
2003; Collera-Zuniga et al. 2004), whereas zeinoxanthin
forms a typical component of oranges and maize (Mele´ndez-
Martı´nez et al. 2003, 2005; Corte´s et al. 2004; Schlatterer &
Breithaupt, 2005). Mercadante & Rodriguez-Amaya (2001)
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pointed out that Brazilian green and leafy vegetables such as
watercress, lettuce, chicory, endive and parsley contain
trace amounts of a-cryptoxanthin, but not b-cryptoxanthin
as often reported. The a-cryptoxanthin standard used by
these researchers was isolated from Amaranthus viridis. How-
ever, as far as we know, the fresh green leaves of carrots serve
as the only important a-cryptoxanthin source (Mu¨ller, 1997).
Health functions of a-cryptoxanthin are essentially not known.
Since a-cryptoxanthin is rarely found in food plants, the
respective concentration in human plasma is expected to be
extremely low (no reliable data available). Consequently, the
use of a-cryptoxanthin as a marker xanthophyll allows the
determination of the intestinal absorption without interference
caused by minor xanthophylls in HPLC analyses. Thus, for the
first time, a pilot human intervention study was designed using
a cellulose-based a-cryptoxanthin formulation without further
additives. The supplement was administered in gelatin soft-gel
capsules in multiple doses of 156mg/d to three male volun-
teers for 16 d and fasting blood samples were analysed
before and after 3, 6, 9, 13 and 16 d.
Experimental design
Materials
Light petroleum (boiling fraction 40–608C), methanol,
acetone, ethyl acetate, ethanol, diethyl ether, n-hexane, silica
gel 60 (0·063–0·200 mm) and 2,6-di-tert-butyl-p-cresol
were purchased from Merck (Darmstadt, Germany). Methyl
tert-butyl ether (MTBE) and KOH (pellets .85 %) were
from Sigma-Aldrich (Taufkirchen, Germany). All solvents
were distilled before use. Ultra-pure water was obtained
from a Milli-Q 185 apparatus (Millipore, Eschborn, Germany).
b-Apo-120-carotenal (standard) was generously provided by
BASF (Ludwigshafen, Germany), b-cryptoxanthin was a gift
from DSM (Kaiseraugst, Switzerland), anhydrolutein I (30,40-
didehydro-b,g-carotene-3-ol) was obtained from CaroteNature
(Lupsingen, Switzerland) and zeinoxanthin was isolated from
canned maize (Zea mays) as described previously (Schlatterer
& Breithaupt, 2005). Cellulose powder (Elcema P100w) was
obtained from Synopharm (Barsbu¨ttel, Germany). The test
kits for in vitro determination of plasma triacylglycerol
(method TR210) or cholesterol (method CH200) were pur-
chased from Randox Laboratories GmbH (Krefeld, Germany).
Carrot leaves from ecological production were obtained from
the Research Station for Husbandry and Organic Farming,
University of Hohenheim (Stuttgart, Germany).
Subjects
Three male individuals aged 22, 29 and 31 years (age 27·3 (SD
4·7) years; BMI 21·6 (SD 0·3) kg/m2) were recruited from staff
and students of the Institute of Food Science
(Hannover, Germany). The characteristics of the participants
are summarised in Table 1. None of them suffered from gas-
trointestinal diseases or took laxatives or drugs lowering
plasma triacylglycerol or cholesterol concentrations. Partici-
pants were requested to keep a normal diet but to avoid
xanthophyll-rich food such as oranges, peaches, red paprika,
papaya, fruit juices, xanthophyll-containing dietary sup-
plements and vitamin-fortified beverages during the depletion
period and during the intervention study. The protocol was
approved by the Medical Ethics Committee of the Medizi-
nische Hochschule (Hannover, Germany). All participants pro-
vided written informed consent.
Study design
The study was designed as a human pilot intervention study
and consisted of a 2-week depletion period followed by a
16 d intervention phase. After taking the first fasting plasma
sample, participants received a breakfast and took the first
supplement under supervision afterwards. Before leaving,
each participant received fifteen capsules in a closed
plastic box and was advised to take one of them after the indi-
vidual breakfast each morning together with some water. All
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Fig. 1. Chemical structures of cryptoxanthin isomers: (A) b-cryptoxanthin
(b, b-carotene-3-ol); (B) a-cryptoxanthin (b,1-carotene-30-ol); (C) zeinox-
anthin (b, 1-carotene-3-ol).
Table 1. Characteristics of the three participants
(Mean values and standard deviations)
Triacylglycerol
(mmol/l)*
Cholesterol
(mmol/l)*
Participant Age (years) Weight (kg) Height (m) BMI (kg/m2) Mean SD Mean SD
1 31 70·0 1·79 21·8 0·62 0·12 4·83 0·76
2 29 60·4 1·69 21·2 0·95 0·19 4·70 0·55
3 22 59·8 1·66 21·7 0·80 0·11 5·28 1·56
* Six determinations per participant.
For details of subjects and procedures, see this page.
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participants were instructed to store the box in a refrigerator at
48C. Further fasting blood samples were taken in the morning
after 3, 6, 9, 13 and 16 d.
Preparation of supplements
Isolation of a-cryptoxanthin from carrot leaves. Fresh green
carrot leaves (2·6 kg, without thick stems) from ecological pro-
duction were homogenised in samples using a bowl cutter
SL11 (cutter spindle 1400 rpm, bowl 19 rpm; 1 min; ADE,
Hamburg, Germany). The resulting mush was filled in samples
of 200 g into glass columns (550 £ 30 mm) and the caroten-
oids were extracted by a mixture of methanol–ethyl acet-
ate–light petroleum (1:1:1, by vol.; 1 litre per column). To
allow for phase separation, the extract was mixed with water
(100 ml). All organic phases were combined, the solvent was
evaporated in vacuum (308C; 50 mbar) and the residue dis-
solved in diethyl ether (600 ml).
Saponification. For removal of lipids and chlorophylls, the
oily residue was dissolved in diethyl ether and saponified over-
night using methanolic KOH (30 %, w/v; 10 ml per 100 ml
ether). To remove alkali, the ether phase was washed and evap-
orated again (308C; 50 mbar). The residue was dissolved in light
petroleum and subjected to flash chromatography (glass column
400 £ 20 mm) on silica gel (10 g) suspended in light petroleum.
Samples of 10 ml were poured onto the column head. The first
band, obtained by elution with light petroleum, consisted
mainly of b-carotene and was discarded. The second band
obtained by elution with light petroleum–acetone (95:5, v/v)
was collected, the solvent completely removed (308C; 50
mbar) and the residue dissolved in ethanol (210 ml). Liquid
chromatography (LC)–MS analyses using an atmospheric
pressure chemical ionisation interface operated in the positive
mode proved the main carotenoid to bea-cryptoxanthin (Schlat-
terer & Breithaupt, 2005). Thus, 10 mg a-cryptoxanthin/210 ml
ethanol were obtained.
Preparation of capsules. Cellulose powder (5·5 g) was sus-
pended in 200 ml of the ethanolica-cryptoxanthin stock solution
in a round-bottomed flask. The solvent was evaporated slowly
(308C; 50 mbar) until a dry free-flowing powder was obtained.
Samples of exactly 100 mg were filled manually in gelatin cap-
sules. Thus, fifty-four capsules were prepared.
Quantification of a-cryptoxanthin. The a-cryptoxanthin
concentration of the capsules was determined after solvent
extraction with methanol–ethyl acetate–light petroleum
(1:1:1, by vol.) by HPLC. Due to similar molar extinction coef-
ficients, a b-cryptoxanthin calibration graph was applied for
quantification of a-cryptoxanthin. The graph was generated by
plotting b-cryptoxanthin peak areas (milli absorption units) v.
the respective concentrations (range 1·08–21·52 mg/l). An
a-cryptoxanthin concentration of 156·3(SD 4·9)mg/capsule (n 3)
was determined. The stability ofa-cryptoxanthin was verified at
the end of the study with additional capsules. A loss of 2·8 %
after 16 d storage at 48C (n 3) was observed. As this stability
was regarded as sufficient for the intervention period no further
antioxidants (for example, a-tocopherol) were added.
Plasma sample preparation
Conventional procedure. At any blood withdrawal, at least
10 ml were sampled from each participant. Immediately after
collection, the plasma was obtained by centrifugation
(2000 g; 198C; 10 min) and stored at 2208C in plastic
caps. The work-up procedure was based on a method of
Khachik et al. (1997). In brief, 1·5 ml plasma were precipi-
tated with ethanol (1 ml containing 1 % 2,6-di-tert-butyl-p-
cresol (w/v)) and mixed on a shaker (1 min). An aliquot
(0·1 ml) of an ethanolic b-apo-120-carotenal standard
(20mg/ml) was added and the solution was mixed again.
To extract the carotenoids, 3 ml n-hexane were added. The
mixture was stirred, the precipitate was spun down using
a centrifuge (644 g; 108C; 5 min), the organic layer was
transferred into a 10 ml brown glass vial, and the extraction
procedure was repeated. The combined organic phases
were evaporated, the residue dissolved in 0·8 ml MTBE–
methanol (1:1, v/v), passed through a 0·45mm membrane
filter and subjected to HPLC–variable wavelength detector
analysis. To determine possible losses during the work-up
procedure, the HPLC peak areas of the standard were
monitored. The recovery of b-apo-120-carotenal from extrac-
tions of all plasma samples accounted for 103 (SD 6)%
(n 18). Plasma triacylglycerol and total cholesterol were
measured manually by using commercial in vitro enzymic
test kits.
Extract for liquid chromatography–mass spectroscopy in
the single ion monitoring mode analysis. To verify a-cryp-
toxanthin identification, one large plasma sample of partici-
pant 3 (5 ml) was extracted three times with a ternary
mixture of methanol, ethyl acetate and light petroleum
(1:1:1, by vol.; 30 ml each). The solvent was removed
(308C, 50 mbar) and the dry residue was saponified as
described earlier (1 ml methanolic KOH (30 %, w/v)–10 ml
diethyl ether) to remove interfering lipids. The residue
was dissolved in 1·0 ml MTBE–methanol (1:1, v/v),
passed through a 0·45mm membrane filter and subjected
to LC–MS analysis in the single ion monitoring (SIM)
mode.
Analysis and chromatography
The HPLC consisted of a modular system HP1100 (Hewlett-
Packard GmbH, Waldbronn, Germany) with the variable
wavelength detector set to 450 nm. For carotenoid separ-
ation, a C30 column (250 £ 4·6 mm internal diameter;
5mm; YMC Europe, Schermbeck, Germany) including a
pre-column (10 £ 4·0 mm internal diameter; 5mm) was
used and kept at 358C. LC–MS was performed on an
HP1100 modular HPLC system, coupled to a Micromass
(Manchester, UK) VG platform II quadrupole mass spec-
trometer equipped with an atmospheric pressure chemical
ionisation interface, operating in the positive mode (scan
range m/z 300–700; data processing by MassLynx 3.2).
The mobile phase consisted of mixtures of methanol–
MTBE–water (81:15:4, by vol. (A) and 6:90:4, by vol.
(B)), starting with 99 % A, followed by a gradient to
obtain 44 % A at 39 min, 0 % A at 45 min, 99 % A at
50 min and isocratic 99 % A from 50–55 min at a flow
rate of 1 ml/min. For LC–MS(SIM) analysis, the following
settings were used: selected mass, 535·4 Da; dwell time,
0·2 s; inter-channel delay, 0·02 s; span, 0·2 Da; injection
volume, 30ml. Further MS parameters have been detailed
previously (Breithaupt et al. 2002).
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Results
Representative HPLC analyses of samples of the
fractionated extract obtained from carrot leaves proved that
a-cryptoxanthin was the main xanthophyll, accompanied by
small amounts of a- and b-carotene, which were co-extracted.
Due to their low concentration (35mg b-carotene/capsule; n 3)
it was anticipated that both would probably not compete with
excess a-cryptoxanthin and thus should not affect absorption
kinetics remarkably. Identification of a-cryptoxantin was
based on its characteristic absorption spectrum (424(sh)/446/
474 nm, determined online in the HPLC solvents), the reten-
tion time and the typical fragmentation pattern found in
LC–MS experiments: the respective mass spectrum showed
a quasimolecular ion at m/z 553·4 (M þ Hþ) with low relative
abundance (9 %) and one daughter ion at m/z 535·4 (M þ H-
H2O
þ) with high intensity (100 %). The loss of water from
the quasimolecular ion occurs readily, a phenomenon typical
for xanthophylls bearing at least one hydroxylated 1-ionone
ring (Mercadante & Rodriguez-Amaya, 2001; Schlatterer &
Breithaupt, 2005). Thus, LC–MS studies clearly supported
the assignment of a-cryptoxanthin.
Figure 2 depicts extended sections of HPLC chromatograms
of representative plasma samples (participant 3; Table 1) before
(trace A) and after supplementation for 16 d (trace B). An
additional trace C shows the same extract as trace B spiked
with a-cryptoxanthin. Trace A proves that the fasting plasma
sample extract contains neither a-cryptoxanthin nor another
xanthophyll co-eluting at the expected retention time. In particu-
lar, the retention time difference between a- and b-crypto-
xanthin (1·5 min) was definitely high enough to avoid peak
overlapping (R 5·0). Although other common plasma carotenes
and xanthophylls appeared in the chromatograms, they did not
interfere with the separation of cryptoxanthin isomers. Their
assignment was based on the respective absorption spectra and
the quasimolecular ions. Particularly, zeinoxanthin and anhy-
drolutein I (30,40-didehydro-b,g-carotene-3-ol), a metabolite of
lutein usually found in human plasma (Khachik et al. 1995),
did not co-elute. Thus, quantification of a-cryptoxanthin could
be accomplished without baseline correction. Peak assignment
was further assured by LC–MS analyses of a concentrated and
saponified plasma sample of participant 3 (Table 1); to enhance
sensitivity, the interface was operated in the SIM mode, using m/
z 535·4 to scan for the typicala-cryptoxanthin fragment ion. The
respective trace is depicted in insert D (Fig. 2), unequivocally
proving correct assignment of a-cryptoxanthin (2). The high
sensitivity of the LC–MS(SIM) analysis applied is obvious if
the a-cryptoxanthin concentration in the concentrated sample
(0·34mmol/l) and a SIM-signal:noise level of 3:1 are considered;
the SIM technique allows for unequivocal determination of con-
centrations up to 0·1mmol/l (55mg/l), corresponding to a plasma
amount of 20 nmol/l (11mg/l).
For quantitative assessment, plasma concentration-time
curves (mmol/l v. d) of all three participants were constructed
(Fig. 3(A)). In each case, the plasma concentrations increased
significantly after 3 d of supplementation. The concentration-
time plots of each individual showed an early maximum
after 6 d, a decline in concentration until day 9 and a gradual
second rise until the end of the study. Maximum concen-
trations reached at the end of the intervention period were
0·077, 0·160 and 0·157mmol/l, respectively.
To estimate the intestinal absorption of a-cryptoxanthin
from the supplement, two assumptions were considered: (i)
4 % of the body weight is plasma (Barua, 1999); (ii) after an
initial phase of about 13 d, a final steady state can be reached.
Such a plateau was recently ascertained by Hartmann et al.
(2004) after giving multiple doses of zeaxanthin (1 mg/d for
42 d) after a booster period of about 2 weeks. Taking into
account that a plasma xanthophyll plateau is in function not
only of the time of supplementation but also of the amount
supplied (which is rather low in the present study), the time
required to reach a plateau is probably more that 16 d. For
example, Olmedilla et al. (2002) described the plateau for-
mation after 4 weeks upon supplementation with several
carotenoids. However, based on a mean concentration of
0·131mmol/l and a mean plasma mass of 2·54 litres (three
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Fig. 2. HPLC chromatograms (extended sections; variable wavelength detector, 450 nm) of representative plasma samples originating from participant 3 (Table 1)
(milli absorption units; mAU): (A) before supplementation; (B) after the intervention (16 d). Trace (C) corresponds to the plasma sample spiked with a-
cryptoxanthin. The insert (D) represents the relevant section of the mass trace (m/z 535·4), suitable for identification of a-cryptoxanthin in liquid chromatography–
MS in single ion monitoring mode analysis, determined in a concentrated and saponified sample extract (5 ml plasma/1 ml final volume) of participant 3. Peak
assignment: 1, b-cryptoxanthin; 2, a-cryptoxanthin; 3, zeinoxanthin; 4, b-apo-120-carotenal (standard); 5, lutein; 6, zeaxanthin; 7, anhydrolutein I (30,40-didehydro-
b,g-carotene-3-ol); 8, a-carotene; 9, b-carotene. For details of subjects and procedures, see p. 372.
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each), the participants had a mean total amount of 0·333mmol
(184mg) a-cryptoxanthin in their circulating plasma after six-
teen doses of the supplement. As only 156mg were adminis-
tered per d, this amount points to both an efficient
absorption of the xanthophyll and even to an enrichment of
a-cryptoxanthin in the human plasma (the clearance period
of a single dose may be 2–3 weeks; Novotny et al. 2005;
Tang et al. 2005). Thus, the results of the present pilot
study suggest a high intestinal absorption of a-cryptoxanthin
even from a minimally formulated cellulose-based
supplement.
To account for potential variations in the triacylglycerol or
total cholesterol levels, a-cryptoxanthin concentrations were
corrected; each a-cryptoxanthin value was divided by the cor-
responding triacylglycerol or total cholesterol value and mul-
tiplied by the mean triacylglycerol or total cholesterol
concentration of all participants. Both triacylglycerol and
total cholesterol concentrations were in the normal range for
all human subjects (desirable concentrations: triacylglycerol
( , 1·25 mmol/l; total cholesterol ( , 5·18 mmol/l; Jordan
et al. 1995; see Table 1 for mean values). a-Cryptoxanthin
plasma responses adjusted for triacylglycerol are shown in
Fig. 3 (B). The time course of triacylglycerol- and total
cholesterol-corrected a-cryptoxanthin concentrations
resembled that of the uncorrected plots. Thus, standardisation
did not influence the shape of the curves.
Areas under the curve (0–16 d; mmol £ d/l) were deter-
mined by the trapezoidal rule without baseline area correction
(SigmaPlot). The respective areas under the curve (0–16 d)
values, calculated from the adjusted concentration-time
plots, were as follows (for participant 1, 2 and 3 respectively):
1·676, 1·423 and 1·644 (standardised to triacylglycerol); 1·329,
1·691 and 1·305 (standardised to total cholesterol). Since area
under the curve values are regarded as proportional to the
bioavailability (Yao et al. 2000), comparison of the triacylgly-
cerol- or cholesterol-adjusted values indicated that there were
only small variations among subjects in the intestinal absorp-
tion of a-cryptoxanthin given in multiple doses.
Discussion
For isolation of a-cryptoxanthin, fresh green carrot leaves
from ecological production were used. Since these plants
were cultivated without the application of pesticides, the leaf
extract did not contain anthropogenic compounds with a poss-
ible health risk for participants. However, the amount of a-
cryptoxanthin available was very limited (3·8 mg/kg leaves).
As a consequence, only three participants were included in
the pilot study, designed to acquire basic data about the intes-
tinal absorption of a-cryptoxanthin administered as multiple
oral doses. Although a-cryptoxanthin is usually not present
as a major xanthophyll in the human diet and the resulting
plasma levels are consequently extremely low, a 2-week
depletion phase preceded the study to reduce the overall caro-
tenoid concentrations usually found in plasma to a base level
and to approximate the individual levels of the participants.
Xanthophylls are lipid soluble and follow the same absorp-
tion pathway as other dietary lipids. Absorption of xantho-
phylls occurs via incorporation into chylomicrons, which
subsequently enter the bloodstream. As a-cryptoxanthin rep-
resents a comparatively polar carotenoid (one hydroxyl func-
tion), it is distributed approximately equally between the
HDL and LDL fractions (Furr & Clark, 1997). After daily
ingestion of a-cryptoxanthin supplements, plasma concen-
tration of all participants increased continuously except for a
slight decrease on day 9, indicating that all participants were
responders. We have no explanation for this temporary
decrease. Due to the time lag it cannot be explained by hepatic
circulation and lipoprotein incorporation, as is known for the
biphasic plasma response to b-carotene within 2 d (Rock,
1997). Furthermore, we do not think that the decrease is a con-
sequence of ingestion of ‘banned’ carotenoid-rich food poss-
ibly leading to a competing effect, since it was observed in
all plasma samples. The second increase found in the a-cryp-
toxanthin concentration cannot be explained by ingestion of
food rich in a-cryptoxanthin because this xanthophyll usually
forms a minor component and is present in the European diet
in extremely low amounts. Moreover, we do not believe that it
is an analytical artefact because all analytical steps were con-
trolled accurately. A second peak, which is usually observed
in concentration-time plots because xanthophylls are incorpor-
ated in VLDL and LDL, did not appear in the present study.
It is understood that the low number of subjects (n 3) is a limi-
tation of the present study. However, the variance in plasma
response between individual subjects (see Fig. 3) was quite
low, a finding being in contrast to results of former studies
reporting broad interindividual variations for other carotenoids.
One explanation may be that all subjects were male and were
within the same age range (27·3 (SD 4·7) years).
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Fig. 3. Plasma concentrations of a-cryptoxanthin studied in dependence of
the sampling time (mmol/l v. d) after taking sixteen capsules containing
156mg a-cryptoxanthin each by three male individuals (B, O, V): (A) without
standardisation; (B) standardised to triacylglycerol plasma concentrations.
For details of subjects and procedures, see p. 372.
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The results of the present pilot study for the first time
suggest a high intestinal absorption of a-cryptoxanthin even
from a minimally formulated cellulose-based supplement.
Although potential health functions of a-cryptoxanthin have
not yet been investigated, this xanthophyll may serve as a
future dietary supplement with both vitamin A activity and
further biological values, not yet known. After optimisation
of the extraction step from carrot leaves – which usually are
regarded as plant waste material – there is a virtual possibility
to launch an optimised formulation on the market.
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